India Diagnostic & Therapeutic Antibodies Market Review Now Available at MarketPublishers.com
25 Jan 2012 • by Natalie Aster
LONDON – India’s market for both diagnostic and therapeutic antibodies is expected to grow at a significant rate in upcoming years. More than 60% of the total antibodies market is currently dominated by diagnostic antibodies segment, which is more mature, has lower entry barriers and is extremely price sensitive. The country’s market for therapeutic antibodies, on the other hand, is still in its infancy and more than half of the globally launched therapeutic monoclonal antibodies are currently not even available. However, the market for therapeutic antibodies is expected to explode, with a CAGR of 27% in the next five years, driven by a rise in healthcare expenditures, increasing affordability, and a number of new product launches.
New research report “Indian Diagnostic & Therapeutic Antibodies Market Report & Forecast: 2011-2016” delivered by IMARC Group has been recently published by Market Publishers Ltd.
Indian Diagnostic & Therapeutic Antibodies Market Report & Forecast: 2011-2016
Published: January, 2012
Price: US$ 1.000,00
The research report provides true and unbiased insights into the antibodies market in India. It enhances understanding of not only the market trends, key drivers & restraints, but also the competitive landscape and outlook of the market through 2016.
Market segments covered include: HIV, hepatitis B, hepatitis C, tuberculosis, dengue, syphilis and oncology.
More new market research reports by the publisher can be found at IMARC Group page.